Transparency and Reporting in the Evaluation of PD1 by Flow Cytometry

Area of Science:

• Biomedical research
• Immunology
• Oncology

Background:

• Flow cytometry is crucial for cancer research, particularly for evaluating biomarkers such as PD1.
• Transparent and reproducible reporting is essential for the validity of flow cytometry studies.
• Inadequate reporting in flow cytometry manuscripts remains a persistent issue.

Purpose of the Study:

• To assess the quality of reporting in flow cytometry studies evaluating PD1 expression in cancer research.
• To identify specific domains where reporting standards are lacking.
• To determine factors influencing reporting quality.

Main Methods:

• A methodological review of 100 recent cancer research manuscripts utilizing flow cytometry for PD1 assessment.
• Evaluation of reporting across six domains: methods, dotplot availability, gating strategy, analysis robustness, figure presentation, and data availability.
• Analysis of the correlation between reporting quality and journal impact factor or journal focus.

Main Results:

• Compliance with basic reporting standards was suboptimal, ranging from 35% to 70% across evaluated domains.
• Reporting of reagents and devices was strong (~90%), but transparency of key data (PD1 dotplots, gating sequences) was insufficient.
• Journal impact factor and specialization did not consistently correlate with higher reporting quality.

Conclusions:

• There is an urgent need to enhance reporting practices in flow cytometry research for cancer biomarkers like PD1.
• Authors, reviewers, and journal editors must collaborate to enforce minimal reporting standards for improved transparency and reproducibility.
• Addressing these reporting gaps is critical for advancing cancer research and reliable biomarker evaluation.